CoChat

CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022

Open access

The DOI matches its Crossref record; 452 of the 460 references it cites were found in a registry or an index.

Abstract

This guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years.It updates the CDC Guideline for Prescribing Opioids for Chronic Pain -United States, 2016 (MMWR Recomm Rep 2016;65[No.RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain.The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative or end-of-life care.The guideline addresses the following four areas: 1) determining whether or not to initiate opioids for pain, 2) selecting opioids and determining opioid dosages, 3) deciding duration of initial opioid prescription and conducting follow-up, and 4) assessing risk and addressing potential harms of opioid use.CDC developed the guideline using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.Recommendations are based on systematic reviews of the scientific evidence and reflect considerations of benefits and harms, patient and clinician values and preferences, and resource allocation.CDC obtained input from the Board of Scientific Counselors of the National Center for Injury Prevention and Control (a federally chartered advisory committee), the public, and peer reviewers.CDC recommends that persons with pain receive appropriate pain treatment, with careful consideration of the benefits and risks of all treatment options in the context of the patient's circumstances.Recommendations should not be applied as inflexible standards of care across patient populations.This clinical practice guideline is intended to improve communication between clinicians and patients about the benefits and risks of pain treatments, including opioid therapy; improve the effectiveness and safety of pain treatment; mitigate pain; improve function and quality of life for patients with pain; and reduce risks associated with opioid pain therapy, including opioid use disorder, overdose, and death.MMWR / November 4, 2022 / Vol.71 / No. 3 US Department of Health and Human Services/Centers for Disease Control and Prevention pain outcomes, psychological distress, overdose, and suicidal ideation and behavior (66-71). RationaleSince release of the 2016 CDC Opioid Prescribing Guideline, new evidence has emerged on the benefits and risks of prescription opioids for both acute and chronic pain, comparisons with nonopioid pain treatments, dosing strategies, opioid dose-dependent effects, risk mitigation strategies, and opioid tapering and discontinuation (7)(8)(9)(10)(11).This evidence includes studies on misapplication of the 2016 CDC Opioid Prescribing Guideline (66), benefits and risks of different tapering strategies and rapid tapering associated with patient harm (68,71-73), challenges in patient access to opioids (6), patient abandonment and abrupt discontinuation of opioids (71), a seminal randomized clinical trial comparing prescription opioids to nonopioid medications on long-term pain outcomes (74), the association of characteristics of initial opioid prescriptions with subsequent likelihood for long-term opioid use (75,76), and the small proportion of opioids used by patients compared with the amount prescribed to them for postoperative pain (77-79).Opioid medications remain a common treatment for pain despite declines in the number of opioid prescriptions after 2012 (58).During 2015-2018, approximately 6% of U.S. adults reported use of one or more prescription opioids during the past 30 days (80), and in 2020, approximately 143 million opioid prescriptions were dispensed from pharmacies in the United States (81).Rates of opioid prescribing continue to vary across states, medical specialties, patient demographics, and pain conditions in ways that cannot be explained by the underlying health status of the population, and often are discordant with the 2016 CDC Opioid Prescribing Guideline recommendations (25,77,(82)(83)(84).The prevalence of prescription opioid misuse and prescription opioid use disorder also has declined in recent years.In 2019, among persons aged ≥12 years in the United States, 9.7 million reported misuse of prescription opioids during the past year (a decrease from 12.5 million in 2015), and 1.4 million met criteria for a past-year prescription opioid use disorder (a decrease from 2.0 million in 2015) (85).However, in 2020, prescription opioids remained the most commonly misused prescription drug in the United States (51).Also in 2020, among those reporting misuse during the past year, 64.6% reported the main reason for their most recent misuse was to "relieve physical pain" compared with 11.3% to "feel good or get high" and 2.3% "because I am hooked or have to have it" (51).Taken together, these factors underscore the need for an updated clinical practice guideline on appropriate opioid prescribing for pain and pain management.MMWR /

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15585/mmwr.rr7103a1

Cites

452 of 452 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 29

  1. Chou R, Wagner J, Ahmed A, Treatments for acute pain: a systematic review. Comparative effectiveness review no. 240. Rockville, MD: Agency for Healthcare Research and Quality; 2020. 33411426
  2. Stagnitti MN. Trends in prescribed outpatient opioid use and expenses in the U.S. civilian noninstitutionalized population, 2002–2012. Statistical brief #478. Rockville, MD: Agency for Healthcare Research and Quality; 2015. https://meps.ahrq.gov/data_files/publications/st478/stat478.shtml 28783287
  3. Laffer A, Murphy R, Winegarden W, et al. An economic analysis of the costs and benefits associated with regular urine drug testing for chronic pain patients in the United States. Nashville, TN: Laffer Associates; 2011. https://www.researchgate.net/publication/268175852_An_Economic_Analysis_of_the_Costs_and_Benefits_Associated_with_Regular_Urine_Drug_Testing_for_Chronic_Pain_Patients_in_the_United_States_Laffer_Associates_An_Economic_Analysis_of_the_Costs_and_Benefit
  4. Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: National Academies Press; 2011. 22553896
  5. Banerjee S, Argáez C. Multidisciplinary treatment programs for patients with acute or subacute pain: a review of clinical effectiveness, cost-effectiveness, and guidelines [Internet]. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2019 May 7. https://www.ncbi.nlm.nih.gov/books/NBK546002/ 31498579
  6. Chou R, Hartung D, Turner J, Opioid treatments for chronic pain. Comparative effectiveness review no. 229. Rockville, MD: Agency for Healthcare Research and Quality; 2020. 32338848 · DOI · Paper page
  7. McDonagh M, Selph S, Buckley D, Nonopioid pharmacologic treatments for chronic pain. Comparative effectiveness review no. 228. Rockville, MD: Agency for Healthcare Research and Quality; 2020. 32338847 · DOI
  8. Skelly A, Chou R, Dettori J, Noninvasive nonpharmacological treatment for chronic pain: a systematic review update. Comparative effectiveness review no. 227. Rockville, MD: Agency for Healthcare Research and Quality; 2020. 32338846 · DOI · Paper page
  9. Chou R, Wagner J, Ahmed A, Treatments for acute pain: a systematic review. Comparative effectiveness review no. 240. Rockville, MD: Agency for Healthcare Research and Quality; 2020. 33411426
  10. Halker Singh R, VanderPluym J, Morrow A, Acute treatments for episodic migraine. Comparative effectiveness review no. 239. Rockville, MD: Agency for Healthcare Research and Quality; 2020. 33411427 · DOI
  11. Heyward J, Jones CM, Compton WM, Coverage of nonpharmacologic treatments for low back pain among US public and private insurers. JAMA Netw Open 2018; 1: e183044. 10.1001/jamanetworkopen.2018.3044 30646222 PMC6324451 · DOI · Paper page
  12. Chou R, Deyo R, Devine B, The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence report/technology assessment no. 218. AHRQ publication no. 14–E005-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2014. 30313000 · DOI · Paper page
  13. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep 2016; 65(No. RR-1): 1– 49. 10.15585/mmwr.rr6501e1 26987082 · DOI · Paper page
  14. Mark TL, Parish W. Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abuse Treat 2019; 103: 58– 63. 10.1016/j.jsat.2019.05.001 31079950 · DOI · Paper page
  15. James JR, Scott JM, Klein JW, Mortality after discontinuation of primary care-based chronic opioid therapy for pain: a retrospective cohort study. J Gen Intern Med 2019; 34: 2749– 55. 10.1007/s11606-019-05301-2 31468341 PMC6854174 · DOI
  16. Krebs EE, Gravely A, Nugent S, Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. JAMA 2018; 319: 872– 82. 10.1001/jama.2018.0899 29509867 PMC5885909 · DOI · Paper page
  17. National Academies of Sciences, Engineering, and Medicine. Framing opioid prescribing guidelines for acute pain: developing the evidence. Washington, DC: National Academies Press; 2019. 32182005
  18. Committee on Approaching Death: Addressing Key End of Life Issues: Institute of Medicine. Dying in America: improving quality and honoring individual preferences near the end of life. Washington, DC: National Academies Press; 2015. 25927121
  19. Banerjee S, McCormack S. Medical cannabis for the treatment of chronic pain: a review of clinical effectiveness and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2019. 31532599
  20. Ostelo RWJG, Deyo RA, Stratford P, Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine 2008; 33: 90– 4. 10.1097/BRS.0b013e31815e3a10 18165753 · DOI · Paper page
  21. Dunn KM, Saunders KW, Rutter CM, Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152: 85– 92. 10.7326/0003-4819-152-2-201001190-00006 20083827 PMC3000551 · DOI · Paper page
  22. Agnoli A, Xing G, Tancredi DJ, Magnan E, Jerant A, Fenton JJ. Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA 2021; 326: 411– 9. 10.1001/jama.2021.11013 34342618 PMC8335575 · DOI · Paper page
  23. Hallvik SE, El Ibrahimi S, Johnston K, Patient outcomes after opioid dose reduction among patients with chronic opioid therapy. Pain 2022; 163: 83– 90. 10.1097/j.pain.0000000000002298 33863865 PMC8494834 · DOI
  24. Sullivan MD, Turner JA, DiLodovico C, D’Appollonio A, Stephens K, Chan Y-F. Prescription opioid taper support for outpatients with chronic pain: a randomized controlled trial. J Pain 2017; 18: 308– 18. 10.1016/j.jpain.2016.11.003 27908840 PMC5337146 · DOI · Paper page
  25. Coffin PO, Behar E, Rowe C, Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med 2016; 165: 245– 52. 10.7326/M15-2771 27366987 PMC5783639 · DOI · Paper page
  26. Lin DH, Lucas E, Murimi IB, Physician attitudes and experiences with Maryland’s prescription drug monitoring program (PDMP). Addiction 2017; 112: 311– 9. 10.1111/add.13620 27658522 · DOI · Paper page
  27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013. · DOI · Paper page
  28. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015; 156: 569– 76. 10.1097/01.j.pain.0000460357.01998.f1 25785523 · DOI · Paper page
  29. National Academies of Sciences, Engineering, and Medicine. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. Washington, DC: National Academies Press; 2017. 29023083

Cited by

See all 1,886

Metadata

Authors
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R.
Affiliations
  • National Center for Injury Prevention and Control (US)
  • Centers for Disease Control and Prevention (US)
  • Oregon Health & Science University (US)
Corresponding author
Dowell, Deborah
Venue
MMWR. Recommendations and Reports
Published
2022-11-04
Volume
71
Issue
3
Pages
1-95
ISSN
  • 1057-5987 (ISSN-L)
  • 1545-8601
OpenAlex
W4308369850
Cited by
1,886
References
460
Citations by year
2026: 504 · 2025: 568 · 2024: 475 · 2023: 324 · 2022: 13
FWCI
304.62
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • MMWR Recommendations and Reports (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Funders
  • Centers for Disease Control and Prevention
  • National Center for Injury Prevention and Control
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
Keywords
opioid prescribing, chronic pain, acute pain, subacute pain, opioid use disorder, opioid overdose, opioid-related harms, opioid tapering, opioid dose titration, opioid risk assessment, non-opioid analgesics, pain management, opioid-related deaths
MeSH terms
Adolescent, Adult, Analgesics, Opioid, Centers for Disease Control and Prevention, U.S., Humans, Opioid-Related Disorders, Quality of Life, United States, Chronic Pain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.